- Home
- CISS vs AZTR Comparison
CISS vs AZTR Comparison
Compare CISS & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- AZTR
- Stock Information
- Founded
- CISS 2022
- AZTR 2014
- Country
- CISS Greece
- AZTR United States
- Employees
- CISS N/A
- AZTR N/A
- Industry
- CISS Marine Transportation
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- AZTR Health Care
- Exchange
- CISS Nasdaq
- AZTR Nasdaq
- Market Cap
- CISS 4.7M
- AZTR 5.0M
- IPO Year
- CISS N/A
- AZTR 2023
- Fundamental
- Price
- CISS $1.02
- AZTR $0.37
- Analyst Decision
- CISS
- AZTR
- Analyst Count
- CISS 0
- AZTR 0
- Target Price
- CISS N/A
- AZTR N/A
- AVG Volume (30 Days)
- CISS 81.4K
- AZTR 17.8M
- Earning Date
- CISS 03-25-2025
- AZTR 03-14-2025
- Dividend Yield
- CISS N/A
- AZTR N/A
- EPS Growth
- CISS N/A
- AZTR N/A
- EPS
- CISS N/A
- AZTR N/A
- Revenue
- CISS $46,661,732.00
- AZTR $97,500.00
- Revenue This Year
- CISS N/A
- AZTR N/A
- Revenue Next Year
- CISS N/A
- AZTR N/A
- P/E Ratio
- CISS N/A
- AZTR N/A
- Revenue Growth
- CISS 491.48
- AZTR N/A
- 52 Week Low
- CISS $0.90
- AZTR $0.23
- 52 Week High
- CISS $29.75
- AZTR $12.00
- Technical
- Relative Strength Index (RSI)
- CISS 32.70
- AZTR 51.23
- Support Level
- CISS $1.15
- AZTR $0.35
- Resistance Level
- CISS $1.21
- AZTR $0.45
- Average True Range (ATR)
- CISS 0.08
- AZTR 0.08
- MACD
- CISS 0.00
- AZTR 0.01
- Stochastic Oscillator
- CISS 32.43
- AZTR 36.26
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.